The cerebrospinal fluid (CSF) findings can help diagnose different types of meningitis. Viral meningitis typically shows clear CSF with a slightly elevated white blood cell count (5-1000 cells/µl, mostly lymphocytes), mildly elevated protein levels, and a normal or slightly low CSF-to-plasma-glucose ratio. Bacterial meningitis, on the other hand, often presents with turbid CSF, a high white blood cell count (>100 cells/µl, mostly neutrophils), elevated protein levels, and a very low CSF-to-plasma-glucose ratio. Fungal meningitis, such as cryptococcal meningitis, usually shows clear or cloudy CSF, a slightly elevated white blood cell count (5-100 cells/µl, mostly lymphocytes), elevated protein levels, and a low CSF-to-plasma-glucose ratio. Tuberculous meningitis typically presents with clear or cloudy CSF, a slightly elevated white blood cell count (5-100 cells/µl, mostly lymphocytes), significantly elevated protein levels, and a very low CSF-to-plasma-glucose ratio. A sub-arachnoid hemorrhage, which is not meningitis, typically presents with a sudden, severe headache and signs of increased intracranial pressure. The CSF in this case often shows xanthochromia.

Understanding Endometrial Cancer: Causes, Stages, and Treatment Options

Endometrial cancer is a type of cancer that affects the lining of the uterus. It is the most common female genital cancer in the developing world, and an estimated 3% of women in developed countries will be diagnosed with this malignancy at some point in their lifetime. Here are some key points to understand about endometrial cancer:

Causes:
– It is more common among women using progestogen-containing oral contraceptives.
– Non-hormonal uterine devices have also been found to be strongly protective.
– There are two pathogenic types of endometrial cancer, one of which is associated with obesity, hyperlipidaemia, signs of hyperoestrogenism, and other disease states.

Stages:
– The FIGO staging system is used to determine the stage of endometrial cancer.
– Staging is the most important prognostic factor.
– The earlier endometrial cancer is diagnosed, the higher the rate of survival at 5 years.

Treatment:
– Standard management of endometrial cancer at diagnosis involves surgery, followed by chemotherapy with or without radiation therapy.
– It is most effectively treated by a combination of radiotherapy and hormone-based chemotherapy.
– The prognosis varies depending on the stage and type of endometrial cancer.

Overall, understanding the causes, stages, and treatment options for endometrial cancer is important for early detection and effective management of this malignancy.

The patient has suffered a third degree perineal tear that has extended beyond the perineal mucosa and muscle, involving the EAS but not the rectal mucosa. Therefore, it is classified as a third degree tear. The appropriate course of action is to repair the tear in theatre by a clinician who is suitably trained. Repairing the tear on the ward by a midwife is not an option as it is a third degree tear. Similarly, repairing it in theatre by a clinician trained for fourth degree tears is not necessary. It is important to note that first degree tears do not require repair, but in this case, as it is a third degree tear, not repairing it would not be appropriate as it may not heal properly.

Perineal tears are a common occurrence during childbirth, and the Royal College of Obstetricians and Gynaecologists (RCOG) has developed guidelines to classify them based on their severity. First-degree tears are superficial and do not require any repair, while second-degree tears involve the perineal muscle and require suturing by a midwife or clinician. Third-degree tears involve the anal sphincter complex and require repair in theatre by a trained clinician, with subcategories based on the extent of the tear. Fourth-degree tears involve the anal sphincter complex and rectal mucosa and also require repair in theatre by a trained clinician.

There are several risk factors for perineal tears, including being a first-time mother, having a large baby, experiencing a precipitant labour, and having a shoulder dystocia or forceps delivery. It is important for healthcare providers to be aware of these risk factors and to provide appropriate care and management during childbirth to minimize the risk of perineal tears. By following the RCOG guidelines and providing timely and effective treatment, healthcare providers can help ensure the best possible outcomes for both mother and baby.

Gram positive cocci are responsible for the majority of bacterial endocarditis cases. The most common culprits include Streptococcus viridans, Staphylococcus aureus (in individuals who use intravenous drugs or have prosthetic valves), and Staphylococcus epidermidis (in those with prosthetic valves). Other less common causes include Enterococcus, Streptococcus bovis, Candida, HACEK group, and Coxiella burnetii. Acute endocarditis is typically caused by Staphylococcus, while subacute cases are usually caused by Streptococcus species. Knowing the common underlying organisms is crucial for determining appropriate empirical antibiotic therapy. For native valve endocarditis, amoxicillin and gentamicin are recommended. Vancomycin and gentamicin are recommended for NVE with severe sepsis, penicillin allergy, or suspected methicillin-resistant Staphylococcus aureus (MRSA). Vancomycin and meropenem are recommended for NVE with severe sepsis and risk factors for gram-negative infection. For prosthetic valve endocarditis, vancomycin, gentamicin, and rifampicin are recommended. Once blood culture results are available, antibiotic therapy can be adjusted to provide specific coverage. Treatment typically involves long courses (4-6 weeks) of intravenous antibiotic therapy.

Aetiology of Infective Endocarditis

Infective endocarditis is a condition that affects patients with previously normal valves, rheumatic valve disease, prosthetic valves, congenital heart defects, intravenous drug users, and those who have recently undergone piercings. The strongest risk factor for developing infective endocarditis is a previous episode of the condition. The mitral valve is the most commonly affected valve.

The most common cause of infective endocarditis is Staphylococcus aureus, particularly in acute presentations and intravenous drug users. Historically, Streptococcus viridans was the most common cause, but this is no longer the case except in developing countries. Streptococcus mitis and Streptococcus sanguinis are the two most notable viridans streptococci, commonly found in the mouth and dental plaque. Coagulase-negative Staphylococci such as Staphylococcus epidermidis are the most common cause of endocarditis in patients following prosthetic valve surgery.

Streptococcus bovis is associated with colorectal cancer, with the subtype Streptococcus gallolyticus being most linked to the condition. Non-infective causes of endocarditis include systemic lupus erythematosus and malignancy. Culture negative causes may be due to prior antibiotic therapy or infections caused by Coxiella burnetii, Bartonella, Brucella, or HACEK organisms (Haemophilus, Actinobacillus, Cardiobacterium, Eikenella, Kingella).

Gastrointestinal Side Effects of Common Medications

Lansoprazole, a proton pump inhibitor, is known to cause gastrointestinal disturbances such as abdominal pain, constipation, flatulence, nausea, vomiting, and diarrhea. This is because it reduces the acidity of the stomach, allowing bacterial flora to proliferate.

Amitriptyline, a tricyclic antidepressant, can cause abdominal pain, anorexia, constipation, increased appetite, nausea, and weight gain or loss. However, it is not associated with diarrhea.

Calcium carbonate, a calcium supplement, can commonly cause gastrointestinal disturbances but is not known to cause diarrhea.

Carbamazepine, an anticonvulsant, commonly causes nausea and vomiting, and rarely constipation and diarrhea. The rarity of diarrhea as a side effect suggests that an alternative option may be more appropriate.

Codeine phosphate, an opioid analgesic, can cause constipation, nausea, and vomiting, but is not known to cause diarrhea.

Chickenpox exposure in pregnancy can pose risks to both the mother and fetus, including fetal varicella syndrome. Post-exposure prophylaxis (PEP) with varicella-zoster immunoglobulin (VZIG) or antivirals should be given to non-immune pregnant women, with timing dependent on gestational age. If a pregnant woman develops chickenpox, specialist advice should be sought and oral aciclovir may be given if she is ≥ 20 weeks and presents within 24 hours of onset of the rash.

Classification of Hypersensitivity Reactions

Hypersensitivity reactions are classified into four types according to the Gell and Coombs classification. Type I, also known as anaphylactic hypersensitivity, occurs when an antigen reacts with IgE bound to mast cells. This type of reaction is responsible for anaphylaxis and atopy, such as asthma, eczema, and hay fever. Type II, or cytotoxic hypersensitivity, happens when cell-bound IgG or IgM binds to an antigen on the cell surface. This type of reaction is associated with autoimmune hemolytic anemia, ITP, Goodpasture’s syndrome, and other conditions. Type III, or immune complex hypersensitivity, occurs when free antigen and antibody (IgG, IgA) combine to form immune complexes. This type of reaction is responsible for serum sickness, systemic lupus erythematosus, post-streptococcal glomerulonephritis, and extrinsic allergic alveolitis. Type IV, or delayed hypersensitivity, is T-cell mediated and is responsible for tuberculosis, graft versus host disease, allergic contact dermatitis, and other conditions.

In recent times, a fifth category has been added to the classification of hypersensitivity reactions. Type V hypersensitivity occurs when antibodies recognize and bind to cell surface receptors, either stimulating them or blocking ligand binding. This type of reaction is associated with Graves’ disease and myasthenia gravis. Understanding the different types of hypersensitivity reactions is important in diagnosing and treating various conditions. Proper identification of the type of reaction can help healthcare professionals provide appropriate treatment and management strategies.

Understanding Somatoform Disorders: Exploring Possible Diagnoses for a Patient with Medically Unexplained Symptoms

This patient presents with medically unexplained symptoms (MUS), which are collectively known as somatoform disorders. The chronicity and large number of diverse symptoms in this case suggest somatisation disorder, a condition that affects 5-10% of repeat attenders in specialist clinics. Somatisation disorder is more common in women than in men and tends to start in early adulthood. Treatment involves psychological interventions (e.g. CBT) and/or antidepressant medication, but patients are frequently reluctant to engage in these.

Other possible diagnoses for MUS include conversion disorder, hypochondriasis, and undifferentiated somatoform disorder. Conversion disorder presents with neurological symptoms, usually some type of loss of function, while hypochondriasis is associated with a persistent preoccupation to have one or more serious and progressive physical illnesses. In hypochondriasis, the patient puts emphasis on the presence of one (or more) determinate illness and on having it diagnosed. In somatisation disorder, such as in this vignette, the emphasis is on the symptoms (for which the patients seeks a medical explanation), rather than on a specific diagnosis. Undifferentiated somatoform disorder is used when the MUS are multiple and persistent, but the diagnostic criteria for somatisation disorder cannot be fulfilled.

Depression is an important co-morbidity in patients with somatoform disorders, but in this vignette, the combination of physical symptoms and the extensive and complex history of contact with primary and secondary services makes somatisation disorder the most likely diagnosis. It is particularly important to use a patient-centred, empathic interview style with patients with somatoform disorders to ensure they receive the appropriate care and support.

Angiotensin-converting enzyme (ACE) inhibitors are commonly used as the first-line treatment for hypertension and heart failure in younger patients. However, they may not be as effective in treating hypertensive Afro-Caribbean patients. These inhibitors are also used to treat diabetic nephropathy and for secondary prevention of ischaemic heart disease. The mechanism of action of ACE inhibitors is to inhibit the conversion of angiotensin I to angiotensin II. They are metabolized in the liver through phase 1 metabolism.

ACE inhibitors may cause side effects such as cough, which occurs in around 15% of patients and may occur up to a year after starting treatment. This is thought to be due to increased bradykinin levels. Angioedema may also occur up to a year after starting treatment. Hyperkalaemia and first-dose hypotension are other potential side effects, especially in patients taking diuretics. ACE inhibitors should be avoided during pregnancy and breastfeeding, and caution should be exercised in patients with renovascular disease, aortic stenosis, or hereditary or idiopathic angioedema.

Patients receiving high-dose diuretic therapy (more than 80 mg of furosemide a day) are at an increased risk of hypotension when taking ACE inhibitors. Before initiating treatment, urea and electrolytes should be checked, and after increasing the dose, a rise in creatinine and potassium may be expected. Acceptable changes include an increase in serum creatinine up to 30% from baseline and an increase in potassium up to 5.5 mmol/l. Patients with undiagnosed bilateral renal artery stenosis may experience significant renal impairment. The current NICE guidelines provide a flow chart for the management of hypertension.

Tumour lysis syndrome is characterized by high levels of potassium and phosphate, as well as low levels of calcium. This is evident in the case history of a lymphoma patient who has started chemotherapy. Allopurinol is the most commonly used prophylaxis, with rasburicase as an alternative. Diuretics are not recommended due to the potential to exacerbate acute kidney injury. It is important to note that steroids and radiotherapy are not common causes of tumour lysis syndrome.

Understanding Tumour Lysis Syndrome

Tumour lysis syndrome (TLS) is a life-threatening condition that can occur during the treatment of high-grade lymphomas and leukaemias. Although it can happen without chemotherapy, it is usually triggered by the introduction of combination chemotherapy. Patients at high risk of TLS should be given prophylactic medication such as IV allopurinol or IV rasburicase to prevent the potentially deadly effects of tumour cell lysis. Rasburicase is a recombinant version of urate oxidase, an enzyme that metabolizes uric acid to allantoin, which is more easily excreted by the kidneys. Patients in lower-risk groups should be given oral allopurinol during chemotherapy cycles to avoid the condition. However, rasburicase and allopurinol should not be given together in the management of tumour lysis syndrome as this reduces the effect of rasburicase.

TLS occurs when tumour cells break down and release chemicals into the body, leading to high levels of potassium and phosphate and a low level of calcium. It should be suspected in any patient presenting with an acute kidney injury in the presence of high phosphate and uric acid levels. From 2004, TLS has been graded using the Cairo-Bishop scoring system, which considers abnormality in two or more of the following within three days before or seven days after chemotherapy: uric acid, potassium, phosphate, and calcium. Clinical tumour lysis syndrome is when laboratory tumour lysis syndrome is present along with increased serum creatinine, cardiac arrhythmia or sudden death, or seizure.

In summary, understanding tumour lysis syndrome is critical in the treatment of high-grade lymphomas and leukaemias. Prophylactic medication can be given to prevent the potentially deadly effects of tumour cell lysis, and the Cairo-Bishop scoring system can be used to grade the severity of the condition. Early detection and management of TLS can improve patient outcomes and prevent complications.

Tumor Markers: Understanding Their Role in Cancer Diagnosis and Therapy Control

Tumor markers are substances produced by cancer cells or normal cells in response to cancer. They can be used in the diagnosis and therapy control of various types of cancer. However, it is important to note that tumor markers are non-specific and can also be elevated in non-cancerous conditions.

Prostate-specific antigen (PSA) is a commonly used tumor marker for prostate cancer. It should be offered to those who request testing or for those who have symptoms suggestive of prostate cancer. PSA levels increase with age, so interpretation should take into account the age of the patient. However, PSA levels can also be elevated in benign prostatic enlargement and prostate inflammation, and can be normal in prostate carcinoma.

Alpha-fetoprotein (AFP) is a tumor marker for hepatocellular carcinoma. However, AFP levels can also be normal in this type of cancer. Lactate dehydrogenase (LDH)-1 isoenzyme levels can be elevated in testicular germ cell tumors, while alkaline phosphatase levels can be raised in cholestasis and Paget’s disease.

Carcinoembryonic antigen (CEA) is a tumor marker for colon cancer, but it is non-specific. The introduction of the PSA test has led to earlier diagnosis of prostate cancer, before metastases into lymph nodes or bone are evident. Bone scans are unnecessary in patients with a PSA <20 ng/ml, and repeated scans during treatment are unnecessary in the absence of clinical indications. In summary, tumor markers can be useful in cancer diagnosis and therapy control, but their interpretation should take into account the patient’s age and other non-cancerous conditions that can elevate their levels.

Statins are drugs that inhibit the action of an enzyme called HMG-CoA reductase, which is responsible for producing cholesterol in the liver. However, they can cause some adverse effects such as myopathy, which includes muscle pain, weakness, and damage, and liver impairment. Myopathy is more common in lipophilic statins than in hydrophilic ones. Statins may also increase the risk of intracerebral hemorrhage in patients who have had a stroke before. Therefore, they should be avoided in these patients. Statins should not be taken during pregnancy and should be stopped if the patient is taking macrolides.

Statins are recommended for people with established cardiovascular disease, those with a 10-year cardiovascular risk of 10% or more, and patients with type 2 diabetes mellitus. Patients with type 1 diabetes mellitus who were diagnosed more than 10 years ago, are over 40 years old, or have established nephropathy should also take statins. It is recommended to take statins at night as this is when cholesterol synthesis takes place. Atorvastatin 20mg is recommended for primary prevention, and the dose should be increased if non-HDL has not reduced for 40% or more. Atorvastatin 80 mg is recommended for secondary prevention.

Bromocriptine is used to treat galactorrhoea, not to induce it.

Understanding Prolactin and Galactorrhoea

Prolactin is a hormone produced by the anterior pituitary gland, and its release is regulated by various physiological factors. Dopamine is the primary inhibitor of prolactin release, and dopamine agonists like bromocriptine can be used to manage galactorrhoea. Galactorrhoea is a condition characterized by the production of breast milk in individuals who are not breastfeeding. It is important to distinguish the causes of galactorrhoea from those of gynaecomastia, which is the enlargement of male breast tissue.

Excess prolactin can lead to different symptoms in men and women. Men may experience impotence, loss of libido, and galactorrhoea, while women may have amenorrhoea and galactorrhoea. Several factors can cause raised prolactin levels, including prolactinoma, pregnancy, oestrogens, stress, exercise, sleep, acromegaly, polycystic ovarian syndrome, and primary hypothyroidism. Additionally, certain medications like metoclopramide, domperidone, phenothiazines, haloperidol, SSRIs, and opioids can also increase prolactin levels.

In summary, understanding prolactin and its effects on the body is crucial in diagnosing and managing conditions like galactorrhoea. Identifying the underlying causes of raised prolactin levels is essential in providing appropriate treatment and improving patient outcomes.

The best option for managing the patient’s unilateral conductive hearing loss, tinnitus, and pinkish tympanic membrane is either a hearing aid or stapedectomy. The tuning fork tests indicate left-sided conductive hearing loss, which is consistent with otosclerosis. This condition is characterized by the replacement of normal bone with vascular spongy bone, leading to progressive conductive hearing loss due to stapes fixation at the oval window. Amoxicillin, betahistine and vestibular rehabilitation exercises, ear syringing, and prochlorperazine are not effective treatments for otosclerosis. Amoxicillin is used to manage acute otitis media, betahistine and vestibular rehabilitation exercises are used to prevent acute attacks in Ménière’s disease, ear syringing is used to remove impacted ear wax, and prochlorperazine is used to decrease dizziness in viral labyrinthitis.

Understanding the Mechanisms of Sumatriptan: A Migraine and Cluster Headache Treatment

Sumatriptan is a medication commonly used to treat migraine and cluster headaches. It works by activating specific serotonin receptors (5-HT1D and 5-HT1B) found on cranial and basilar arteries, causing vasoconstriction of these blood vessels. This medication can be administered orally, by subcutaneous injection, or intranasally.

It is important to note that sumatriptan has no effect on adrenergic receptors or acetylcholinesterase receptors. It is also not a cyclooxygenase (COX) inhibitor or an opioid receptor agonist or antagonist.

In addition to its effects on blood vessels, sumatriptan has been shown to decrease the activity of the trigeminal nerve, which is responsible for its effectiveness in treating cluster headaches.

Overall, understanding the mechanisms of sumatriptan can help healthcare professionals and patients better understand how this medication works to alleviate the symptoms of migraine and cluster headaches.

Propranolol, a non-selective beta-blocker, is utilized for the prevention of oesophageal bleeding. Bisoprolol and metoprolol, both cardio-selective beta-blockers, are not as effective as propranolol for the extended management of varices. Terlipressin, a vasopressin analogue, is recommended for the immediate treatment of variceal bleeding.

Variceal haemorrhage is a serious condition that requires prompt management. The initial treatment involves resuscitation of the patient before endoscopy. Correcting clotting with FFP and vitamin K is important, as is the use of vasoactive agents such as terlipressin or octreotide. Prophylactic IV antibiotics are also recommended to reduce mortality in patients with liver cirrhosis. Endoscopic variceal band ligation is the preferred method of treatment, and the use of a Sengstaken-Blakemore tube or Transjugular Intrahepatic Portosystemic Shunt (TIPSS) may be necessary if bleeding cannot be controlled. Propranolol and EVL are effective in preventing rebleeding and mortality, and are recommended by NICE guidelines. Proton pump inhibitor cover is given to prevent EVL-induced ulceration.

If the COC is initiated on the first day of the menstrual cycle, it becomes effective immediately. However, if it is started on any other day, additional contraception such as condoms should be used for the first 7 days. The injection, implant, IUS, and POP require 7 days to become effective, while the IUD is effective immediately upon insertion.

Counselling for Women Considering the Combined Oral Contraceptive Pill

Women who are considering taking the combined oral contraceptive pill (COC) should receive counselling on the potential harms and benefits of the pill. The COC is highly effective if taken correctly, with a success rate of over 99%. However, there is a small risk of blood clots, heart attacks, and strokes, as well as an increased risk of breast and cervical cancer.

In addition to discussing the potential risks and benefits, women should also receive advice on how to take the pill. If the COC is started within the first 5 days of the menstrual cycle, there is no need for additional contraception. However, if it is started at any other point in the cycle, alternative contraception should be used for the first 7 days. Women should take the pill at the same time every day and should be aware that intercourse during the pill-free period is only safe if the next pack is started on time.

There have been recent changes to the guidelines for taking the COC. While it was previously recommended to take the pill for 21 days and then stop for 7 days to mimic menstruation, it is now recommended to discuss tailored regimes with women. This is because there is no medical benefit to having a withdrawal bleed, and options include never having a pill-free interval or taking three 21-day packs back-to-back before having a 4 or 7 day break.

Women should also be informed of situations where the efficacy of the pill may be reduced, such as vomiting within 2 hours of taking the pill, medication that induces diarrhoea or vomiting, or taking liver enzyme-inducing drugs. It is also important to discuss sexually transmitted infections and precautions that should be taken with enzyme-inducing antibiotics such as rifampicin.

Overall, counselling for women considering the COC should cover a range of topics to ensure that they are fully informed and able to make an informed decision about their contraceptive options.

To avoid prolonged manual restraint, it is recommended to consider rapid tranquillisation or seclusion as alternatives. Prolonged physical restraint poses both physical and emotional risks for both patients and staff. Handcuffs and other mechanical restraints should only be used in exceptional circumstances in high-secure settings. It is important to avoid releasing an agitated patient from restraint as it could be dangerous for staff and other patients. Patients should not be carried during any kind of restraint.

Understanding Psychosis

Psychosis is a term used to describe a person’s experience of perceiving things differently from those around them. This can manifest in various ways, including hallucinations, delusions, thought disorganization, alogia, tangentiality, clanging, and word salad. Associated features may include agitation/aggression, neurocognitive impairment, depression, and thoughts of self-harm. Psychotic symptoms can occur in a range of conditions, such as schizophrenia, depression, bipolar disorder, puerperal psychosis, brief psychotic disorder, neurological conditions, and drug use. The peak age of first-episode psychosis is around 15-30 years.

Treatment Options for Ethmoidal Sinusitis and Orbital Cellulitis

Ethmoidal sinusitis is a common cause of orbital cellulitis, which requires prompt treatment to prevent complications. The most effective treatment for ethmoidal sinusitis is surgical drainage of the sinuses to remove the pus and debris. Antibiotics are also necessary to aid recovery, but they should be administered after the drainage procedure.

While there are several antibiotics that can be used to treat orbital cellulitis, such as cefuroxime, metronidazole, co-amoxiclav, and Tazocin®, they are not sufficient to address the underlying cause of the condition. Therefore, drainage of the ethmoid sinuses is the definitive treatment for ethmoidal sinusitis and orbital cellulitis.

In summary, the treatment options for ethmoidal sinusitis and orbital cellulitis include surgical drainage of the sinuses followed by antibiotics. Antibiotics alone are not enough to treat the condition, and the choice of antibiotic may vary depending on the patient’s age and other factors.

The recommended initial treatments for spasticity in multiple sclerosis are baclofen and gabapentin.

Multiple sclerosis is a condition that cannot be cured, but its treatment aims to reduce the frequency and duration of relapses. In the case of an acute relapse, high-dose steroids may be administered for five days to shorten its length. However, it is important to note that steroids do not affect the degree of recovery. Disease-modifying drugs are used to reduce the risk of relapse in patients with MS. These drugs are typically indicated for patients with relapsing-remitting disease or secondary progressive disease who have had two relapses in the past two years and are able to walk a certain distance unaided. Natalizumab, ocrelizumab, fingolimod, beta-interferon, and glatiramer acetate are some of the drugs used to reduce the risk of relapse in MS.

Fatigue is a common problem in MS patients, and amantadine is recommended by NICE after excluding other potential causes such as anaemia, thyroid problems, or depression. Mindfulness training and CBT are other options for managing fatigue. Spasticity is another issue that can be addressed with first-line drugs such as baclofen and gabapentin, as well as physiotherapy. Cannabis and botox are currently being evaluated for their effectiveness in managing spasticity. Bladder dysfunction is also a common problem in MS patients, and anticholinergics may worsen symptoms in some patients. Ultrasound is recommended to assess bladder emptying, and intermittent self-catheterisation may be necessary if there is significant residual volume. Gabapentin is the first-line treatment for oscillopsia, which is a condition where visual fields appear to oscillate.

Chondrocalcinosis is a useful indicator for differentiating between pseudogout and gout.

The presence of chondrocalcinosis can be observed in an x-ray, which helps to distinguish between pseudogout and gout. In older individuals, joint space loss and osteoarthritic-like changes are common and may be caused by pseudogout.

Pseudogout, also known as acute calcium pyrophosphate crystal deposition disease, is a type of microcrystal synovitis that occurs when calcium pyrophosphate dihydrate crystals are deposited in the synovium. This condition is more common in older individuals, but those under 60 years of age may develop it if they have underlying risk factors such as haemochromatosis, hyperparathyroidism, low magnesium or phosphate levels, acromegaly, or Wilson’s disease. The knee, wrist, and shoulders are the most commonly affected joints, and joint aspiration may reveal weakly-positively birefringent rhomboid-shaped crystals. X-rays may show chondrocalcinosis, which appears as linear calcifications of the meniscus and articular cartilage in the knee. Treatment involves joint fluid aspiration to rule out septic arthritis, as well as the use of NSAIDs or steroids, as with gout.

Temporal arteritis is likely the cause of a constant throbbing headache, pain while chewing, and tenderness in the scalp. These symptoms are not typical of a migraine, which usually involves pain on one side of the head, sensitivity to light, nausea/vomiting, and sometimes an aura. A subarachnoid hemorrhage typically presents with a sudden, severe headache in the occipital region. Tension headaches are often described as a dull, band-like pain across the forehead. Cluster headaches are characterized by intense pain around the eye, accompanied by tearing, redness, and a stuffy nose.

Understanding Temporal Arteritis

Temporal arteritis is a type of large vessel vasculitis that often overlaps with polymyalgia rheumatica (PMR). It is characterized by changes in the affected artery that skip certain sections while damaging others. This condition typically affects individuals who are over 60 years old and has a rapid onset, usually occurring in less than a month. The most common symptoms include headache and jaw claudication, while vision testing is a crucial investigation for all patients.

Temporal arteritis can lead to various ocular complications, with anterior ischemic optic neuropathy being the most common. This results from the occlusion of the posterior ciliary artery, leading to ischemia of the optic nerve head. Patients may experience temporary visual loss or even permanent visual loss, which is the most feared complication of this condition. Other symptoms may include diplopia, tender and palpable temporal artery, and features of PMR such as aching, morning stiffness in proximal limb muscles, lethargy, depression, low-grade fever, anorexia, and night sweats.

To diagnose temporal arteritis, doctors may look for raised inflammatory markers such as an ESR of over 50 mm/hr or elevated CRP levels. A temporal artery biopsy may also be performed to check for skip lesions. Urgent high-dose glucocorticoids should be given as soon as the diagnosis is suspected, and an ophthalmologist should review patients with visual symptoms on the same day. Treatment may also involve bone protection with bisphosphonates and low-dose aspirin, although the evidence supporting the latter is weak.

In summary, temporal arteritis is a serious condition that requires prompt diagnosis and treatment to prevent irreversible visual damage. Patients who experience symptoms such as headache, jaw claudication, and visual disturbances should seek medical attention immediately.

Premature Ovarian Insufficiency: Causes and Management

Premature ovarian insufficiency is a condition where menopausal symptoms and elevated gonadotrophin levels occur before the age of 40. It affects approximately 1 in 100 women and can be caused by various factors such as idiopathic reasons, family history, bilateral oophorectomy, radiotherapy, chemotherapy, infection, autoimmune disorders, and resistant ovary syndrome. The symptoms of premature ovarian insufficiency are similar to those of normal menopause, including hot flushes, night sweats, infertility, secondary amenorrhoea, raised FSH and LH levels, and low oestradiol.

Management of premature ovarian insufficiency involves hormone replacement therapy (HRT) or a combined oral contraceptive pill until the age of the average menopause, which is 51 years. It is important to note that HRT does not provide contraception in case spontaneous ovarian activity resumes. Early diagnosis and management of premature ovarian insufficiency can help alleviate symptoms and improve quality of life for affected women.

The police can utilize Section 136 to transport individuals who may be exhibiting indications of mental illness and pose a danger to themselves or others to a secure location. This section is only valid for a maximum of 24 hours, during which time a Mental Health Act Assessment can be scheduled. In rare cases, it may be extended by an additional 12 hours. It is only applicable to individuals in public areas, not in their own or someone else’s residence – Section 135 is required for this. It does not authorize involuntary treatment. A secure location can be a hospital, the individual’s home or a friend’s home, or, if no other option is available, a police station.

Sectioning under the Mental Health Act is a legal process used for individuals who refuse voluntary admission. This process excludes patients who are under the influence of drugs or alcohol. There are several sections under the Mental Health Act that allow for different types of admission and treatment.

Section 2 allows for admission for assessment for up to 28 days, which is not renewable. An Approved Mental Health Professional (AMHP) or the nearest relative (NR) can make the application on the recommendation of two doctors, one of whom should be an approved consultant psychiatrist. Treatment can be given against the patient’s wishes.

Section 3 allows for admission for treatment for up to 6 months, which can be renewed. An AMHP and two doctors, both of whom must have seen the patient within the past 24 hours, can make the application. Treatment can also be given against the patient’s wishes.

Section 4 is used as an emergency 72-hour assessment order when a section 2 would involve an unacceptable delay. A GP and an AMHP or NR can make the application, which is often changed to a section 2 upon arrival at the hospital.

Section 5(2) allows a doctor to legally detain a voluntary patient in hospital for 72 hours, while section 5(4) allows a nurse to detain a voluntary patient for 6 hours.

Section 17a allows for Supervised Community Treatment (Community Treatment Order) and can be used to recall a patient to the hospital for treatment if they do not comply with the conditions of the order in the community, such as taking medication.

Section 135 allows for a court order to be obtained to allow the police to break into a property to remove a person to a Place of Safety. Section 136 allows for someone found in a public place who appears to have a mental disorder to be taken by the police to a Place of Safety. This section can only be used for up to 24 hours while a Mental Health Act assessment is arranged.

According to NICE (2017) guidelines, patients with asthma should be prescribed a SABA as the first step of treatment. However, if a patient experiences symptoms three or more times per week or night waking, they should also be prescribed a low-dose ICS inhaler as the second step of treatment. This is also necessary for patients who have had an acute exacerbation requiring oral corticosteroids in the past two years. In this case, the patient’s symptoms are not well-controlled with a SABA alone, and she experiences frequent symptoms and night waking. Therefore, she requires a low-dose ICS inhaler, and the only option available is budesonide.

Adding a salmeterol inhaler is not appropriate at this stage, as LABAs are only used as the fourth step of treatment if a patient is not controlled with a SABA, low-dose ICS, and a trial of LTRAs. Similarly, adding montelukast and a beclomethasone inhaler is not appropriate, as LTRAs are only added if a patient is still not controlled on a low-dose ICS and a SABA. However, it may be appropriate to trial beclomethasone without montelukast.

Continuing with the current salbutamol-only treatment is not appropriate, as the patient’s asthma is poorly controlled, which increases the risk of morbidity and mortality. Regular salbutamol has no role in the management of asthma, as it does not improve outcomes and may even worsen them by downregulating beta receptors that are important for bronchodilation.

The management of asthma in adults has been updated by NICE in 2017, following the 2016 BTS guidelines. One of the significant changes is in ‘step 3’, where patients on a SABA + ICS whose asthma is not well controlled should be offered a leukotriene receptor antagonist instead of a LABA. NICE does not follow the stepwise approach of the previous BTS guidelines, but to make the guidelines easier to follow, we have added our own steps. The steps range from newly-diagnosed asthma to SABA +/- LTRA + one of the following options, including increasing ICS to high-dose, a trial of an additional drug, or seeking advice from a healthcare professional with expertise in asthma. Maintenance and reliever therapy (MART) is a form of combined ICS and LABA treatment that is only available for ICS and LABA combinations in which the LABA has a fast-acting component. It should be noted that NICE does not recommend changing treatment in patients who have well-controlled asthma simply to adhere to the latest guidance. The definitions of what constitutes a low, moderate, or high-dose ICS have also changed, with <= 400 micrograms budesonide or equivalent being a low dose, 400 micrograms - 800 micrograms budesonide or equivalent being a moderate dose, and > 800 micrograms budesonide or equivalent being a high dose for adults.

In the management of alcohol withdrawal, decreasing doses of long-acting benzodiazepines are commonly used. This is because long-term alcohol use can cause an imbalance in the brain’s excitatory and inhibitory neurotransmitters, leading to symptoms of an overactive sympathetic nervous system when alcohol is suddenly stopped. These symptoms can include restlessness, sweating, tremors, and agitation, and can even progress to seizures and delirium tremens. Long-acting benzodiazepines, such as chlordiazepoxide or diazepam, potentiate the action of the inhibitory neurotransmitter GABA and can help mitigate the risk of seizures and other withdrawal symptoms. Carbamazepine, an anticonvulsant, may also be used as a second-line medication if benzodiazepines are not appropriate. Haloperidol, a typical antipsychotic, is not typically used in alcohol withdrawal as it does not reduce the risk of seizures. Lorazepam, a short-acting benzodiazepine, is also not typically used in this context as long-acting benzodiazepines are preferred for their longer half-life.

Alcohol withdrawal occurs when an individual who has been consuming alcohol chronically suddenly stops or reduces their intake. Chronic alcohol consumption enhances the inhibitory effects of GABA in the central nervous system, similar to benzodiazepines, and inhibits NMDA-type glutamate receptors. However, alcohol withdrawal leads to the opposite effect, resulting in decreased inhibitory GABA and increased NMDA glutamate transmission. Symptoms of alcohol withdrawal typically start at 6-12 hours and include tremors, sweating, tachycardia, and anxiety. Seizures are most likely to occur at 36 hours, while delirium tremens, which includes coarse tremors, confusion, delusions, auditory and visual hallucinations, fever, and tachycardia, peak at 48-72 hours.

Patients with a history of complex withdrawals from alcohol, such as delirium tremens, seizures, or blackouts, should be admitted to the hospital for monitoring until their withdrawals stabilize. The first-line treatment for alcohol withdrawal is long-acting benzodiazepines, such as chlordiazepoxide or diazepam, which are typically given as part of a reducing dose protocol. Lorazepam may be preferable in patients with hepatic failure. Carbamazepine is also effective in treating alcohol withdrawal, while phenytoin is said to be less effective in treating alcohol withdrawal seizures.

Overview of Viral Infections and Their Clinical Manifestations

Hepatitis A, B, and C, leptospirosis, and cytomegalovirus (CMV) are all viral infections that can cause a range of clinical manifestations. Hepatitis A is typically transmitted through ingestion of contaminated food and is most common in resource-poor regions. Leptospirosis is associated with exposure to rodents and contaminated water or soil. Hepatitis B is transmitted through blood and sexual contact, while hepatitis C is most commonly spread through injection drug use. CMV is typically asymptomatic but can cause severe disease in immunocompromised individuals. Understanding the transmission and clinical manifestations of these viral infections is important for accurate diagnosis and appropriate treatment.

Managing Haematuria: Causes, Testing, and Referral Guidelines

The management of haematuria can be challenging due to the lack of widely followed guidelines. Haematuria is classified as either visible or non-visible, with the latter being found in approximately 2.5% of the population. Transient or spurious non-visible haematuria can be caused by factors such as urinary tract infections, menstruation, vigorous exercise, or sexual intercourse. Persistent non-visible haematuria, on the other hand, may be indicative of underlying conditions such as cancer, stones, benign prostatic hyperplasia, prostatitis, urethritis, or renal causes like IgA nephropathy or thin basement membrane disease.

Current evidence does not support routine screening for haematuria, but patients taking aspirin or warfarin should still be investigated. Urine dipstick is the preferred test for detecting haematuria, and persistent non-visible haematuria is defined as blood being present in 2 out of 3 samples tested 2-3 weeks apart. Renal function, albumin:creatinine (ACR) or protein:creatinine ratio (PCR), and blood pressure should also be checked. NICE urgent cancer referral guidelines recommend urgent referral for patients aged 45 years or older with unexplained visible haematuria or aged 60 years or older with unexplained non-visible haematuria and either dysuria or a raised white cell count on a blood test. Patients under 40 years of age with normal renal function, no proteinuria, and normotension may be managed in primary care.

In conclusion, managing haematuria requires careful consideration of the underlying causes and appropriate testing. Referral guidelines can help guide healthcare professionals in determining which patients require urgent or non-urgent referral for further investigation.

Understanding Premenstrual Syndrome (PMS)

Premenstrual syndrome (PMS) is a condition that affects women during the luteal phase of their menstrual cycle. It is characterized by emotional and physical symptoms that can range from mild to severe. PMS only occurs in women who have ovulatory menstrual cycles and does not occur before puberty, during pregnancy, or after menopause.

Emotional symptoms of PMS include anxiety, stress, fatigue, and mood swings. Physical symptoms may include bloating and breast pain. The severity of symptoms varies from woman to woman, and management options depend on the severity of symptoms.

Mild symptoms can be managed with lifestyle advice, such as getting enough sleep, exercising regularly, and avoiding smoking and alcohol. Specific advice includes eating regular, frequent, small, balanced meals that are rich in complex carbohydrates.

Moderate symptoms may benefit from a new-generation combined oral contraceptive pill (COCP), such as Yasmin® (drospirenone 3 mg and ethinylestradiol 0.030 mg). Severe symptoms may benefit from a selective serotonin reuptake inhibitor (SSRI), which can be taken continuously or just during the luteal phase of the menstrual cycle (for example, days 15-28, depending on the length of the cycle). Understanding PMS and its management options can help women better cope with this common condition.

Differentiating Coarctation of the Aorta from Other Congenital Heart Diseases

Coarctation of the aorta is a congenital heart disease that can present in different forms and be associated with various genetic abnormalities. Preductal coarctation of the aorta, which is more common in Turner syndrome, is characterized by aortic stenosis proximal to the insertion of the ductus arteriosus. On the other hand, post-ductal coarctation is the adult type of the disease and is not associated with any genetic abnormalities. Patent ductus arteriosus, another congenital heart disease, is not associated with any genetic abnormalities. Tetralogy of Fallot, which is associated with di George syndrome, and transposition of the great vessels are also congenital heart diseases that can be differentiated from coarctation of the aorta. Understanding the different clinical features and associations of these diseases is crucial for accurate diagnosis and appropriate management.